The FDA has granted Regenerative Medicine Advanced Therapy designation to NouvNeu001, a cell therapy for Parkinson’s disease.
NouvNeu001, developed by iRegene, is the first allogeneic cell therapy globally to hold both RMAT and Fast Track designations, according to a Jan. 19 company news release. The therapy is designed to replace lost dopaminergic neurons and restore dopamine production in patients with Parkinson’s disease, the second most common neurodegenerative disorder worldwide.
Phase 1 clinical trial data showed motor function improvements of up to 52.82% in the low-dose group and 54.67% in the ON-medication state at 12 months. Benefits were sustained through 15 months post-treatment.
The drugmaker plans to expand its pipeline of cell-based treatments targeting multiple system atrophy, early-onset Parkinson’s and retinal degeneration, with additional products in clinical or preclinical stages.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
